Oncolytics Biotech (ONCY) Other Accumulated Expenses (2018 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Other Accumulated Expenses of $123528.0 for Q3 2025, up 7.33% year-over-year from $115089.4 in Q3 2024, and down 82.57% quarter-over-quarter from $708721.7 in Q2 2025.
Oncolytics Biotech (ONCY) Other Accumulated Expenses (2018 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Other Accumulated Expenses for 7 consecutive years, with $123528.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Accumulated Expenses rose 7.33% year-over-year to $123528.0; the TTM figure through Sep 2025 stood at $123528.0 (up 7.33% YoY), while the FY2024 annual figure was $1.1 million, up 357.19% from the prior year.
- Other Accumulated Expenses retreated to $123528.0 in Q3 2025 per ONCY's latest filing, from $708721.7 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.2 million in Q4 2024 and bottomed at -$100865.2 in Q2 2021.
- Historically, Other Accumulated Expenses has averaged $374555.0 across 4 years, with a median of $243865.8 in 2023.
- Annual changes were most pronounced in 2021 — Other Accumulated Expenses tumbled 121.44% — and 2024, when it soared 374.95%.
- Oncolytics Biotech's Other Accumulated Expenses stood at $279254.3 in 2021, then slipped by 12.67% to $243865.8 in 2023, then jumped by 374.95% to $1.2 million in 2024, then tumbled by 89.33% to $123528.0 in 2025.
- Business Quant data shows ONCY's Other Accumulated Expenses at $123528.0 in Q3 2025, $708721.7 in Q2 2025, and $369365.7 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 123,527.95 |
| Jun 30, 2025 | 708,721.67 |
| Mar 31, 2025 | 369,365.73 |
| Dec 31, 2024 | 1.16 Mn |
| Sep 30, 2024 | 115,089.39 |
| Jun 30, 2024 | 920,505.95 |
| Mar 31, 2024 | 233,023.55 |
| Dec 31, 2023 | 243,865.79 |
| Sep 30, 2023 | 69,371.53 |
| Dec 31, 2021 | 279,254.30 |
| Jun 30, 2021 | -100,865.16 |
| Dec 31, 2020 | 95,103.27 |
| Sep 30, 2020 | 412,373.00 |
| Jun 30, 2020 | 470,507.00 |
| Mar 31, 2020 | 712,982.00 |
| Dec 31, 2019 | 641,763.97 |
| Sep 30, 2019 | -39,338.00 |
| Jun 30, 2019 | -39,338.00 |
| Mar 31, 2019 | 19,645.00 |
| Dec 31, 2018 | 61,322.00 |